ALLO Overview

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Wall Street analysts forecast ALLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLO is8.50 USD with a low forecast of 5.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Allogene Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

Allogene Therapeutics Inc. EPS for the last quarter amounts to -0.19 USD, decreased -40.62

Allogene Therapeutics Inc (ALLO) has 226 emplpoyees as of March 11 2026.

Today ALLO has the market capitalization of 609.02M USD.